Michael Vinzenz KnoppMD, PhD
Michael Knopp, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses his research on imaging biomarkers for disease characterization and response assessment. Dr Knopp also studies imaging technology development and validation, and imaging biomarker development and validation.
One of his recent clinical trials revealed that, after receiving two cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD), PET2-positive patients with response-adapted therapy based on interim PET imaging had a much higher two-year progression-free survival rate than expected. Dr Knopp has authored many articles in well-known publications, including Journal of Clinical Oncology, Journal of Magnetic Resonance Imaging, Cancer and International Journal of Radiation Oncology * Biology * Physics.